Results 141 to 150 of about 724,283 (165)
Some of the next articles are maybe not open access.
A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases
Expert Review of Clinical Immunology, 2015The development of biologic drugs has undoubtedly enhanced the spectrum of treatments available for immune-mediated inflammatory rheumatic diseases such as rheumatoid arthritis. However, despite their clear clinical benifits, use of biologics is often hindered by their high costs.
openaire +2 more sources
Efficacy of biosimilar infliximab CT-P13 among inpatients with severe steroid-refractory colitis
International Journal of Colorectal Disease, 2020In this study, we evaluate the efficacy and safety of the biosimilar infliximab, CT-P13, in the treatment of inpatients with severe steroid-refractory colitis.A retrospective cohort study of adult colitis patients (UC or isolated Crohn's colitis) admitted to the University of Chicago inflammatory bowel disease inpatient service between January 2018 and
Jacob E. Ollech +8 more
openaire +2 more sources
Immunotherapy, 2020
The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several 'biosimilar' drugs of anti-TNF agents have been developed.
Seung Wook Hong +2 more
openaire +2 more sources
The introduction of anti-TNFs, such as infliximab (IFX), has revolutionized the treatment of immune-mediated inflammatory diseases. Anti-TNF agents have shown outstanding efficacy and long-term improvement of clinical outcomes, but the cost has been relatively high. Out of this concern, several 'biosimilar' drugs of anti-TNF agents have been developed.
Seung Wook Hong +2 more
openaire +2 more sources
Expert Opinion on Biological Therapy, 2020
Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD).
Tommaso Lorenzo Parigi +3 more
openaire +2 more sources
Biologic drugs have significantly improved the treatment of ulcerative colitis (UC) and Crohn's disease (CD). However, the availability of these drugs is limited by their high cost. Infliximab was the first biologic to be approved for inflammatory bowel diseases (IBD).
Tommaso Lorenzo Parigi +3 more
openaire +2 more sources
CT-P13 (Inflectra™, Remsima™) monitoring in patients with inflammatory bowel disease
Biologicals, 2016The approval of infliximab biosimilars Remsima™ and Inflectra™ (CT-P13) for patients with inflammatory bowel disease (IBD) is a promising step to reduce treatment costs. Since monitoring of Remicade™ serum trough levels and anti-Remicade™ immunogenicity hold an important significance in treatment modalities, no data about monitoring of drug serum ...
Kornelius, Schulze +5 more
openaire +2 more sources
CT-P13 (an infliximab biosimilar): a guide to its use in the EU
Drugs & Therapy Perspectives, 2015CT-P13 (Remsima™; Inflectra™) is an infliximab biosimilar approved in the EU for use in all indications for which reference infliximab is approved, including rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
openaire +1 more source
Infliximab biosimilar CT-P13 in Crohn's disease
The Lancet, 2019Gecse, Krisztina B., D'Haens, Geert R.
openaire +3 more sources
Infliximab biosimilar CT-P13 for inflammatory bowel disease
The Lancet Gastroenterology & Hepatology, 2018Bonovas S, Peyrin-Biroulet L, Danese S
openaire +3 more sources
Discovery of a 0.42-s pulsar in the ultraluminous X-ray source NGC 7793 P13
Monthly Notices of the Royal Astronomical Society: Letters, 2017Gian Luca Israel +2 more
exaly